Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global company in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. This news page aggregates announcements, press releases, and corporate updates related to Waters, giving readers a focused view of developments that affect the company and its markets.
Investors and industry professionals can use this feed to follow Waters’ product launches, financial results, and strategic initiatives. Recent news has highlighted new technologies such as the Xevo Charge Detection Mass Spectrometer (CDMS), which Waters describes as enabling direct mass detection for large biomolecules relevant to next-generation therapeutics, and a Charged Aerosol Detector designed for use with the company’s Empower chromatography data system. These announcements illustrate how Waters is addressing analytical challenges in pharmaceuticals, biotherapeutics, food analysis, and environmental testing.
The news stream also features quarterly earnings releases, where Waters reports sales performance, instrument and recurring revenue trends, and commentary from management. In addition, Waters issues updates on investor conference presentations and on the planned combination with BD’s Biosciences & Diagnostic Solutions business via a Reverse Morris Trust transaction, as described in its press releases and Form 8-K filings.
By reviewing Waters-related news in one place, readers can track themes such as instrument replacement cycles, adoption of new chromatography and mass spectrometry products, and the company’s expansion into adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. Bookmark this page to monitor ongoing disclosures and media releases that shape the narrative around WAT stock and Waters’ role in regulated, high-volume testing and scientific markets.
Waters Corporation (NYSE:WAT) has launched the waters_connect System Monitoring application, a cloud-native Software-as-a-Service (SaaS) solution for real-time remote monitoring of chromatography instruments using Empower Software. This innovative tool enhances laboratory efficiency by providing immediate visibility into instrument availability, enabling quick response to changing priorities. It primarily targets high-volume QA/QC laboratories, assisting in reducing product release sample turnaround times and optimizing resource usage. The application is currently available in Europe and North America.
Waters Corporation (NYSE:WAT) will hold its Q4 2022 financial results conference call on February 15, 2023, at 8:00 a.m. eastern time. The live webcast can be accessed on their investor relations website. A replay will be available until March 1, 2023. Waters is a leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis, with over 7,800 employees and operations in more than 35 countries.
Summary not available.
Waters Corporation (NYSE:WAT) will present at the J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 PM PST. Udit Batra, CEO, will discuss key topics with investors. The event can be accessed via a live webcast on Waters' investor relations website, with a replay available for 30 days. Waters has been a leader in analytical instruments and software for over 60 years, specializing in chromatography and mass spectrometry, with a presence in over 100 countries and more than 7,800 employees.
Summary not available.
Waters Corporation (NYSE:WAT) has appointed Dan Brennan and Mark Vergnano to its Board of Directors, effective November 23, 2022. Brennan, currently CFO at Boston Scientific, and Vergnano, former CEO of The Chemours Company, bring extensive experience crucial for Waters' growth strategy. Their addition follows a robust board refreshment process, making the board nine members strong, with eight independent. Chairman Dr. Flemming Ornskov highlights their potential to enhance operational and financial expertise as Waters implements its growth initiatives.
Waters Corporation has launched a new PFAS quantitation workflow that simplifies the detection of Per- and Polyfluoroalkyl Substances (PFAS) in various environmental samples. This end-to-end solution can measure parts-per-quadrillion (ppq) levels, exceeding regulatory limits, and includes automated data processing through the waters_connect software. This innovation aims to streamline laboratory operations while reducing manual errors in PFAS measurement, addressing increasing regulatory requirements.
Waters Corporation (NYSE:WAT) will participate in the Evercore ISI HealthconX Conference on November 29th, 2022. Udit Batra, Ph.D., the President and CEO, will engage in a virtual fireside chat from 1:00-1:45 PM EST. Investors can access the live webcast on the company's investor relations website and a replay will be available for 30 days.
Waters is a global leader in analytical instruments and software, with over 7,800 employees and operations in over 35 countries, specializing in chromatography and mass spectrometry.
Summary not available.
Waters Corporation (NYSE: WAT) reported Q3 2022 sales of $709 million, reflecting a 7% increase as reported and 15% in constant currency. Key highlights include a 21% surge in instrument sales and strong revenue growth across all major geographies, particularly a 23% increase in China. Recurring revenues rose 10% in constant currency. GAAP EPS remained stable at $2.60, while non-GAAP EPS slightly declined to $2.64. Waters raised its full-year 2022 sales growth guidance to 11.5%-12%, despite a 6% unfavorable currency impact. For Q4, it projects sales growth of 6%-8% and non-GAAP EPS of $3.66-$3.76, factoring in currency headwinds.